KR20080107466A - 대사 장애 치료용 8-헤테로아릴퓨린 mnk2 억제제 - Google Patents
대사 장애 치료용 8-헤테로아릴퓨린 mnk2 억제제 Download PDFInfo
- Publication number
- KR20080107466A KR20080107466A KR1020087024592A KR20087024592A KR20080107466A KR 20080107466 A KR20080107466 A KR 20080107466A KR 1020087024592 A KR1020087024592 A KR 1020087024592A KR 20087024592 A KR20087024592 A KR 20087024592A KR 20080107466 A KR20080107466 A KR 20080107466A
- Authority
- KR
- South Korea
- Prior art keywords
- amine
- purin
- ethyl
- pyridin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 16
- 239000003112 inhibitor Substances 0.000 title abstract description 6
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims abstract description 29
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims abstract description 28
- 208000008589 Obesity Diseases 0.000 claims abstract description 21
- 235000020824 obesity Nutrition 0.000 claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims description 108
- -1 hydroxy, hydroxy Chemical group 0.000 claims description 100
- 238000000034 method Methods 0.000 claims description 77
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 27
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 206010006895 Cachexia Diseases 0.000 claims description 7
- 125000004442 acylamino group Chemical group 0.000 claims description 7
- 125000004945 acylaminoalkyl group Chemical group 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 201000001883 cholelithiasis Diseases 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 208000001130 gallstones Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 201000002859 sleep apnea Diseases 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 208000030814 Eating disease Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims description 5
- 235000014632 disordered eating Nutrition 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- QZTXFEFHGSSLLO-UHFFFAOYSA-N n-(4-fluorophenyl)-8-pyridin-4-yl-7h-purin-2-amine Chemical compound C1=CC(F)=CC=C1NC1=NC=C(N=C(N2)C=3C=CN=CC=3)C2=N1 QZTXFEFHGSSLLO-UHFFFAOYSA-N 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 4
- PVUIOAOUQPLJTC-UHFFFAOYSA-N 9-cyclopropyl-8-pyridin-4-yl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3C=CN=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 PVUIOAOUQPLJTC-UHFFFAOYSA-N 0.000 claims description 4
- PYWHJJIUMDLXKQ-UHFFFAOYSA-N 9-cyclopropyl-n-(2-fluorophenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound FC1=CC=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 PYWHJJIUMDLXKQ-UHFFFAOYSA-N 0.000 claims description 4
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- WZJMKKBGBBEOHS-UHFFFAOYSA-N 2,2,2-trifluoro-n-[[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CNC(=O)C(F)(F)F)C=C1 WZJMKKBGBBEOHS-UHFFFAOYSA-N 0.000 claims description 3
- HYGPEUXRWYLOIN-UHFFFAOYSA-N 3-[2-(3-methoxyanilino)-8-pyrimidin-4-ylpurin-9-yl]propanenitrile Chemical compound COC1=CC=CC(NC=2N=C3N(CCC#N)C(C=4N=CN=CC=4)=NC3=CN=2)=C1 HYGPEUXRWYLOIN-UHFFFAOYSA-N 0.000 claims description 3
- GSSIKTIGYYEYMO-UHFFFAOYSA-N 3-[8-(2-aminopyrimidin-4-yl)-2-(3-methoxyanilino)purin-9-yl]propanenitrile Chemical compound COC1=CC=CC(NC=2N=C3N(CCC#N)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 GSSIKTIGYYEYMO-UHFFFAOYSA-N 0.000 claims description 3
- ZEBHVVDCUCLCHN-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-ethyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=C(N)N=CC=4)=NC3=CN=2)=C1 ZEBHVVDCUCLCHN-UHFFFAOYSA-N 0.000 claims description 3
- XQNSTUNYRQGUTD-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-ethyl-n-(4-fluorophenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3C=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 XQNSTUNYRQGUTD-UHFFFAOYSA-N 0.000 claims description 3
- NAZLPTWWZCLEGV-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-n-(3-methoxyphenyl)-9-propan-2-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C(C)C)C(C=4C=C(N)N=CC=4)=NC3=CN=2)=C1 NAZLPTWWZCLEGV-UHFFFAOYSA-N 0.000 claims description 3
- BJXSTXQFDAMJBO-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 BJXSTXQFDAMJBO-UHFFFAOYSA-N 0.000 claims description 3
- NZBVUKPKBZXNEM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(3-fluorophenyl)purin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=C(F)C=CC=4)=NC=C3N=2)C2CC2)=N1 NZBVUKPKBZXNEM-UHFFFAOYSA-N 0.000 claims description 3
- LBUYYVMDIUYIQM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(3-methylphenyl)purin-2-amine Chemical compound CC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 LBUYYVMDIUYIQM-UHFFFAOYSA-N 0.000 claims description 3
- YIBMLVFQUNJWTN-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(4-fluorophenyl)purin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)C2CC2)=N1 YIBMLVFQUNJWTN-UHFFFAOYSA-N 0.000 claims description 3
- ZWVBYQWMUYSQFE-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-phenylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=CC=CC=4)=NC=C3N=2)C2CC2)=N1 ZWVBYQWMUYSQFE-UHFFFAOYSA-N 0.000 claims description 3
- XBMKEEBOFTZPDJ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-fluoro-4-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C(F)=C1 XBMKEEBOFTZPDJ-UHFFFAOYSA-N 0.000 claims description 3
- XQBFABALBUOMFZ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-fluorophenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(F)=C1 XQBFABALBUOMFZ-UHFFFAOYSA-N 0.000 claims description 3
- XPWBIWZPFJXZAP-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-ethylphenyl)purin-2-amine Chemical compound C1=CC(CC)=CC=C1NC1=NC=C(N=C(C=2N=C(N)N=CC=2)N2CC)C2=N1 XPWBIWZPFJXZAP-UHFFFAOYSA-N 0.000 claims description 3
- ZXHUFUJXDSAJCQ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-fluoro-2-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1C ZXHUFUJXDSAJCQ-UHFFFAOYSA-N 0.000 claims description 3
- KDYPIICQVSPKMD-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-fluoro-3-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(C)=C1 KDYPIICQVSPKMD-UHFFFAOYSA-N 0.000 claims description 3
- YKXGRIRISAGLQD-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-fluorophenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 YKXGRIRISAGLQD-UHFFFAOYSA-N 0.000 claims description 3
- ZKXXIMSVOLKANW-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C=C1 ZKXXIMSVOLKANW-UHFFFAOYSA-N 0.000 claims description 3
- DVPGOFKHIYJKOF-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(5,6,7,8-tetrahydronaphthalen-1-yl)purin-2-amine Chemical compound N=1C2=CN=C(NC=3C=4CCCCC=4C=CC=3)N=C2N(CC)C=1C1=CC=NC(N)=N1 DVPGOFKHIYJKOF-UHFFFAOYSA-N 0.000 claims description 3
- ZIKBLUKPDFVYJQ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(5-fluoro-2-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(F)=CC=C1C ZIKBLUKPDFVYJQ-UHFFFAOYSA-N 0.000 claims description 3
- CJINNKPHGFAJBZ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,3-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(F)=C1F CJINNKPHGFAJBZ-UHFFFAOYSA-N 0.000 claims description 3
- JROADSMIBPKINP-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,3-dihydro-1h-inden-4-yl)-9-ethylpurin-2-amine Chemical compound N=1C2=CN=C(NC=3C=4CCCC=4C=CC=3)N=C2N(CC)C=1C1=CC=NC(N)=N1 JROADSMIBPKINP-UHFFFAOYSA-N 0.000 claims description 3
- UAOBQSOZRAWNRN-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,3-dihydro-1h-inden-5-yl)-9-ethylpurin-2-amine Chemical compound N=1C2=CN=C(NC=3C=C4CCCC4=CC=3)N=C2N(CC)C=1C1=CC=NC(N)=N1 UAOBQSOZRAWNRN-UHFFFAOYSA-N 0.000 claims description 3
- GZHQOWSFWOKEST-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,3-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(C)=C1C GZHQOWSFWOKEST-UHFFFAOYSA-N 0.000 claims description 3
- LRPGHDNBVLBTRM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,4-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1F LRPGHDNBVLBTRM-UHFFFAOYSA-N 0.000 claims description 3
- ZXCKOEZXNLZFED-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,4-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C=C1C ZXCKOEZXNLZFED-UHFFFAOYSA-N 0.000 claims description 3
- YMROIJUEVYGXLM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,5-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(C)=CC=C1C YMROIJUEVYGXLM-UHFFFAOYSA-N 0.000 claims description 3
- QSUJBCZKUIYDAI-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,6-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=C(F)C=CC=C1F QSUJBCZKUIYDAI-UHFFFAOYSA-N 0.000 claims description 3
- UNYFPFJIOAAHDI-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2-chlorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC=C1Cl UNYFPFJIOAAHDI-UHFFFAOYSA-N 0.000 claims description 3
- LKLPSMRQPSLPDC-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3,4-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(F)=C1 LKLPSMRQPSLPDC-UHFFFAOYSA-N 0.000 claims description 3
- DDXSNLQGUWIDOP-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3,4-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C(C)=C1 DDXSNLQGUWIDOP-UHFFFAOYSA-N 0.000 claims description 3
- PJQSHEDWLPFTEM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3,5-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(F)=CC(F)=C1 PJQSHEDWLPFTEM-UHFFFAOYSA-N 0.000 claims description 3
- BYAYUIDASASDNM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3-chlorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=C(Cl)C=CC=4)=NC=C3N=2)C2CC2)=N1 BYAYUIDASASDNM-UHFFFAOYSA-N 0.000 claims description 3
- OPGGSXVCGUHKTG-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3-chlorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(Cl)=C1 OPGGSXVCGUHKTG-UHFFFAOYSA-N 0.000 claims description 3
- LLKWJSVYFODKGI-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3-methoxyphenyl)-9-propan-2-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C(C)C)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 LLKWJSVYFODKGI-UHFFFAOYSA-N 0.000 claims description 3
- JZRNPHRSVLUEDZ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(4-chloro-2-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C(=CC(Cl)=CC=4)F)=NC=C3N=2)C2CC2)=N1 JZRNPHRSVLUEDZ-UHFFFAOYSA-N 0.000 claims description 3
- BUWCGYCENTWUQM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(4-chlorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(Cl)C=C1 BUWCGYCENTWUQM-UHFFFAOYSA-N 0.000 claims description 3
- GISBRRIKYIRFBV-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-9-cyclopropyl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound C1=NC(Cl)=CC(C=2N(C3=NC(NCCC=4SC=CC=4)=NC=C3N=2)C2CC2)=C1 GISBRRIKYIRFBV-UHFFFAOYSA-N 0.000 claims description 3
- PQTLIVNTYOKNQG-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-9-cyclopropyl-n-phenylpurin-2-amine Chemical compound C1=NC(Cl)=CC(C=2N(C3=NC(NC=4C=CC=CC=4)=NC=C3N=2)C2CC2)=C1 PQTLIVNTYOKNQG-UHFFFAOYSA-N 0.000 claims description 3
- WVKZPZQQIQZLRA-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-9-ethyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=C(Cl)N=CC=4)=NC3=CN=2)=C1 WVKZPZQQIQZLRA-UHFFFAOYSA-N 0.000 claims description 3
- QMYWKEOMADJKGX-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-n-(3-methoxyphenyl)-9-propan-2-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C(C)C)C(C=4C=C(Cl)N=CC=4)=NC3=CN=2)=C1 QMYWKEOMADJKGX-UHFFFAOYSA-N 0.000 claims description 3
- WYQFVKIKCKBYHG-UHFFFAOYSA-N 8-(6-aminopyridin-3-yl)-9-ethyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=NC(N)=CC=4)=NC3=CN=2)=C1 WYQFVKIKCKBYHG-UHFFFAOYSA-N 0.000 claims description 3
- YNDWIOYGPZEHHJ-UHFFFAOYSA-N 8-(6-aminopyridin-3-yl)-9-ethyl-n-(4-fluorophenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3C=NC(N)=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 YNDWIOYGPZEHHJ-UHFFFAOYSA-N 0.000 claims description 3
- PAPJNYYKUHRNAN-UHFFFAOYSA-N 8-pyridin-4-yl-n-(2-thiophen-2-ylethyl)-7h-purin-2-amine Chemical compound N=1C=C2N=C(C=3C=CN=CC=3)NC2=NC=1NCCC1=CC=CS1 PAPJNYYKUHRNAN-UHFFFAOYSA-N 0.000 claims description 3
- VKQRYONUADIMLP-UHFFFAOYSA-N 9-cyclopropyl-8-[2-(methylamino)pyrimidin-4-yl]-n-(3-methylphenyl)purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(C)C=CC=4)=NC=C3N=2)C2CC2)=N1 VKQRYONUADIMLP-UHFFFAOYSA-N 0.000 claims description 3
- OSBKRHDCCLRWLM-UHFFFAOYSA-N 9-cyclopropyl-8-[2-(methylamino)pyrimidin-4-yl]-n-phenylpurin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=CC=CC=4)=NC=C3N=2)C2CC2)=N1 OSBKRHDCCLRWLM-UHFFFAOYSA-N 0.000 claims description 3
- NGGDOPRXNBBLKF-UHFFFAOYSA-N 9-cyclopropyl-8-pyrimidin-4-yl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3N=CN=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 NGGDOPRXNBBLKF-UHFFFAOYSA-N 0.000 claims description 3
- MNZMPTJPAKSVHS-UHFFFAOYSA-N 9-cyclopropyl-n-(3-ethylphenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=C(NC)N=CC=4)=NC3=CN=2)=C1 MNZMPTJPAKSVHS-UHFFFAOYSA-N 0.000 claims description 3
- ZZQRWDRUNISRQQ-UHFFFAOYSA-N 9-cyclopropyl-n-(3-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(F)C=CC=4)=NC=C3N=2)C2CC2)=N1 ZZQRWDRUNISRQQ-UHFFFAOYSA-N 0.000 claims description 3
- CDWRRSAITRSBIC-UHFFFAOYSA-N 9-cyclopropyl-n-(3-methoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 CDWRRSAITRSBIC-UHFFFAOYSA-N 0.000 claims description 3
- JBXJDBLTKOEXSR-UHFFFAOYSA-N 9-cyclopropyl-n-(3-methoxyphenyl)-8-pyrimidin-4-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=CN=CC=4)=NC3=CN=2)=C1 JBXJDBLTKOEXSR-UHFFFAOYSA-N 0.000 claims description 3
- XZGGGDHKYSGMNC-UHFFFAOYSA-N 9-cyclopropyl-n-(4-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)C2CC2)=N1 XZGGGDHKYSGMNC-UHFFFAOYSA-N 0.000 claims description 3
- NTEZSWHZWMLNNS-UHFFFAOYSA-N 9-cyclopropyl-n-[3-(2-morpholin-4-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C=1C=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=CC=1OCCN1CCOCC1 NTEZSWHZWMLNNS-UHFFFAOYSA-N 0.000 claims description 3
- DMHMLTMJTDGBPZ-UHFFFAOYSA-N 9-cyclopropyl-n-[4-(methylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CNC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 DMHMLTMJTDGBPZ-UHFFFAOYSA-N 0.000 claims description 3
- CTAJMNAZMJJEDD-UHFFFAOYSA-N 9-cyclopropyl-n-[4-[2-(methylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CCNC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 CTAJMNAZMJJEDD-UHFFFAOYSA-N 0.000 claims description 3
- KSFYQXBAGPACQL-UHFFFAOYSA-N 9-cyclopropyl-n-phenyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1CC1N1C2=NC(NC=3C=CC=CC=3)=NC=C2N=C1C1=CC=NC=C1 KSFYQXBAGPACQL-UHFFFAOYSA-N 0.000 claims description 3
- LIIWSMMSGDTMAE-UHFFFAOYSA-N 9-ethyl-n-(3-ethylphenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4N=C(NC)N=CC=4)=NC3=CN=2)=C1 LIIWSMMSGDTMAE-UHFFFAOYSA-N 0.000 claims description 3
- DSRXMYCCMKHUAE-UHFFFAOYSA-N 9-ethyl-n-(4-fluoro-3-methoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(F)C(OC)=C1 DSRXMYCCMKHUAE-UHFFFAOYSA-N 0.000 claims description 3
- RWUGJXUJUMDRNM-UHFFFAOYSA-N 9-ethyl-n-[3-(2-methoxyethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(OCCOC)=C1 RWUGJXUJUMDRNM-UHFFFAOYSA-N 0.000 claims description 3
- FQJRBITYKOCDKP-UHFFFAOYSA-N 9-ethyl-n-[3-(2-morpholin-4-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1OCCN1CCOCC1 FQJRBITYKOCDKP-UHFFFAOYSA-N 0.000 claims description 3
- SVFRGHJASFOKEE-UHFFFAOYSA-N 9-ethyl-n-[3-(2-piperidin-1-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1OCCN1CCCCC1 SVFRGHJASFOKEE-UHFFFAOYSA-N 0.000 claims description 3
- PWQVITAVWFKFIW-UHFFFAOYSA-N 9-ethyl-n-[3-(ethylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound CCNCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 PWQVITAVWFKFIW-UHFFFAOYSA-N 0.000 claims description 3
- HHHOWXQLRMMJDE-UHFFFAOYSA-N 9-ethyl-n-[3-[(propan-2-ylamino)methyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CNC(C)C)=C1 HHHOWXQLRMMJDE-UHFFFAOYSA-N 0.000 claims description 3
- ZVULPPVKKPIYNY-UHFFFAOYSA-N 9-ethyl-n-[3-[2-(ethylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound CCNCCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 ZVULPPVKKPIYNY-UHFFFAOYSA-N 0.000 claims description 3
- MTFACQXGLMPJIB-UHFFFAOYSA-N 9-ethyl-n-[3-[2-(propan-2-ylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CCNC(C)C)=C1 MTFACQXGLMPJIB-UHFFFAOYSA-N 0.000 claims description 3
- RMIGYMSGAIENSJ-UHFFFAOYSA-N 9-ethyl-n-[4-(2-methoxyethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(OCCOC)C=C1 RMIGYMSGAIENSJ-UHFFFAOYSA-N 0.000 claims description 3
- HVMQAXFYSZQCJI-UHFFFAOYSA-N 9-ethyl-n-[4-(2-morpholin-4-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1OCCN1CCOCC1 HVMQAXFYSZQCJI-UHFFFAOYSA-N 0.000 claims description 3
- BGZQEYTYZMHHBG-UHFFFAOYSA-N 9-ethyl-n-[4-(2-piperidin-1-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1OCCN1CCCCC1 BGZQEYTYZMHHBG-UHFFFAOYSA-N 0.000 claims description 3
- AGQPZCNJZAXRBB-UHFFFAOYSA-N 9-ethyl-n-[4-(ethylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CNCC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2CC)C2=N1 AGQPZCNJZAXRBB-UHFFFAOYSA-N 0.000 claims description 3
- VRVGCRZYHMPPEW-UHFFFAOYSA-N 9-ethyl-n-[4-(methylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CNC)C=C1 VRVGCRZYHMPPEW-UHFFFAOYSA-N 0.000 claims description 3
- AZFBBBZAAXJYDR-UHFFFAOYSA-N 9-ethyl-n-[4-[2-(ethylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CCNCC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2CC)C2=N1 AZFBBBZAAXJYDR-UHFFFAOYSA-N 0.000 claims description 3
- LNBJHYNELVITJQ-UHFFFAOYSA-N 9-ethyl-n-[4-[2-(methylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCNC)C=C1 LNBJHYNELVITJQ-UHFFFAOYSA-N 0.000 claims description 3
- UFEPWKZHQMKCAS-UHFFFAOYSA-N 9-ethyl-n-[4-[2-(propan-2-ylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCNC(C)C)C=C1 UFEPWKZHQMKCAS-UHFFFAOYSA-N 0.000 claims description 3
- ZFHPAFXEJGOZDW-UHFFFAOYSA-N 9-methyl-8-pyridin-4-yl-n-[3-(2-pyrrolidin-1-ylethyl)phenyl]purin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCN1CCCC1 ZFHPAFXEJGOZDW-UHFFFAOYSA-N 0.000 claims description 3
- LUCZZVHZJFEMCD-UHFFFAOYSA-N 9-methyl-8-pyridin-4-yl-n-[4-(2-pyrrolidin-1-ylethyl)phenyl]purin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCN1CCCC1 LUCZZVHZJFEMCD-UHFFFAOYSA-N 0.000 claims description 3
- PRMFGMRJTDHQLR-UHFFFAOYSA-N 9-methyl-n-[3-(2-morpholin-4-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCN1CCOCC1 PRMFGMRJTDHQLR-UHFFFAOYSA-N 0.000 claims description 3
- LAKWSPNLJOWAPV-UHFFFAOYSA-N 9-methyl-n-[3-(2-piperazin-1-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCN1CCNCC1 LAKWSPNLJOWAPV-UHFFFAOYSA-N 0.000 claims description 3
- GOOFAHMXVRLDHU-UHFFFAOYSA-N 9-methyl-n-[3-(2-piperidin-1-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCN1CCCCC1 GOOFAHMXVRLDHU-UHFFFAOYSA-N 0.000 claims description 3
- AJELQPXEYGUQPF-UHFFFAOYSA-N 9-methyl-n-[3-(morpholin-4-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CN1CCOCC1 AJELQPXEYGUQPF-UHFFFAOYSA-N 0.000 claims description 3
- BPEWWPDJYWGJER-UHFFFAOYSA-N 9-methyl-n-[3-(piperazin-1-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CN1CCNCC1 BPEWWPDJYWGJER-UHFFFAOYSA-N 0.000 claims description 3
- HCSLILLYWYXDJV-UHFFFAOYSA-N 9-methyl-n-[3-(piperidin-1-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CN1CCCCC1 HCSLILLYWYXDJV-UHFFFAOYSA-N 0.000 claims description 3
- WYCKFLGURNNCKO-UHFFFAOYSA-N 9-methyl-n-[3-[2-(4-methylpiperazin-1-yl)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1CN(C)CCN1CCC1=CC=CC(NC=2N=C3N(C)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 WYCKFLGURNNCKO-UHFFFAOYSA-N 0.000 claims description 3
- WICOBPMYLCUPKO-UHFFFAOYSA-N 9-methyl-n-[4-(2-morpholin-4-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCN1CCOCC1 WICOBPMYLCUPKO-UHFFFAOYSA-N 0.000 claims description 3
- VDGIEODIGVRUHU-UHFFFAOYSA-N 9-methyl-n-[4-(2-piperidin-1-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCN1CCCCC1 VDGIEODIGVRUHU-UHFFFAOYSA-N 0.000 claims description 3
- ULXPBRKJHKFUAU-UHFFFAOYSA-N 9-methyl-n-[4-(methylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CNC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 ULXPBRKJHKFUAU-UHFFFAOYSA-N 0.000 claims description 3
- QPQLPPDWPUQPRA-UHFFFAOYSA-N 9-methyl-n-[4-(morpholin-4-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CN1CCOCC1 QPQLPPDWPUQPRA-UHFFFAOYSA-N 0.000 claims description 3
- ULGLNVPCXHERLJ-UHFFFAOYSA-N 9-methyl-n-[4-(piperazin-1-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CN1CCNCC1 ULGLNVPCXHERLJ-UHFFFAOYSA-N 0.000 claims description 3
- RAAGZBFPKOIRAF-UHFFFAOYSA-N 9-methyl-n-[4-(piperidin-1-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CN1CCCCC1 RAAGZBFPKOIRAF-UHFFFAOYSA-N 0.000 claims description 3
- OLIBBAODESAITO-UHFFFAOYSA-N 9-methyl-n-[4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1CN(C)CCN1CCC(C=C1)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 OLIBBAODESAITO-UHFFFAOYSA-N 0.000 claims description 3
- XSUYJNHRKYXUTP-UHFFFAOYSA-N 9-methyl-n-[4-[2-(methylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CCNC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 XSUYJNHRKYXUTP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 3
- FWHYCPPXCXIERA-UHFFFAOYSA-N ethyl 4-[2-(4-fluoroanilino)-9-methylpurin-8-yl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OCC)=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)C)=C1 FWHYCPPXCXIERA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 3
- NPAVJSROLVUUBX-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N=1C2=CN=C(NC=3C=C4OCCOC4=CC=3)N=C2N(CC)C=1C1=CC=NC=C1 NPAVJSROLVUUBX-UHFFFAOYSA-N 0.000 claims description 3
- HQEJLLJOQVQIRW-UHFFFAOYSA-N n-(3,4-difluorophenyl)-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(F)C(F)=C1 HQEJLLJOQVQIRW-UHFFFAOYSA-N 0.000 claims description 3
- QZFRMJLDOBBTNQ-UHFFFAOYSA-N n-(3-chlorophenyl)-9-cyclopropyl-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(Cl)C=CC=4)=NC=C3N=2)C2CC2)=N1 QZFRMJLDOBBTNQ-UHFFFAOYSA-N 0.000 claims description 3
- IRPQXSQAPKVCNJ-UHFFFAOYSA-N n-(3-methoxyphenyl)-8-[2-(methylamino)pyrimidin-4-yl]-9-propan-2-ylpurin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(OC)C=CC=4)=NC=C3N=2)C(C)C)=N1 IRPQXSQAPKVCNJ-UHFFFAOYSA-N 0.000 claims description 3
- DNZFCTAPXIOPCB-UHFFFAOYSA-N n-(3-methoxyphenyl)-9-propan-2-yl-8-pyrimidin-4-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C(C)C)C(C=4N=CN=CC=4)=NC3=CN=2)=C1 DNZFCTAPXIOPCB-UHFFFAOYSA-N 0.000 claims description 3
- YIGZCAPHNFVCDA-UHFFFAOYSA-N n-(4-fluorophenyl)-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 YIGZCAPHNFVCDA-UHFFFAOYSA-N 0.000 claims description 3
- FVZYADGFRJUBRR-UHFFFAOYSA-N n-(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)-1,3-benzothiazol-6-amine Chemical compound C1CC1N1C2=NC(NC=3C=C4SC=NC4=CC=3)=NC=C2N=C1C1=CC=NC=C1 FVZYADGFRJUBRR-UHFFFAOYSA-N 0.000 claims description 3
- MUGWGRLZTQAQSZ-UHFFFAOYSA-N n-[2-[4-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]-n-methylacetamide Chemical compound C1=CC(CCN(C)C(C)=O)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 MUGWGRLZTQAQSZ-UHFFFAOYSA-N 0.000 claims description 3
- SXCZYSHPDFNYFF-UHFFFAOYSA-N n-[2-[4-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]acetamide Chemical compound C1=CC(CCNC(=O)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 SXCZYSHPDFNYFF-UHFFFAOYSA-N 0.000 claims description 3
- PZSKMDBKCUQLSQ-UHFFFAOYSA-N n-[2-[4-[(9-ethyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]-n-methylacetamide Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCN(C)C(C)=O)C=C1 PZSKMDBKCUQLSQ-UHFFFAOYSA-N 0.000 claims description 3
- ILIFXEKKMSMPGQ-UHFFFAOYSA-N n-[2-[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenoxy]ethyl]acetamide Chemical compound C1=CC(OCCNC(=O)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 ILIFXEKKMSMPGQ-UHFFFAOYSA-N 0.000 claims description 3
- MNBAMJCWNUBYCM-UHFFFAOYSA-N n-[2-[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]acetamide Chemical compound C1=CC(CCNC(=O)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 MNBAMJCWNUBYCM-UHFFFAOYSA-N 0.000 claims description 3
- BVKIHXDYFHWWLF-UHFFFAOYSA-N n-[3-(aminomethyl)phenyl]-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound NCC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 BVKIHXDYFHWWLF-UHFFFAOYSA-N 0.000 claims description 3
- XZQIWHORMUJUAO-UHFFFAOYSA-N n-[3-(aminomethyl)phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CN)=C1 XZQIWHORMUJUAO-UHFFFAOYSA-N 0.000 claims description 3
- YMOIYAVQZHMYKO-UHFFFAOYSA-N n-[3-(aminomethyl)phenyl]-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CN)=C1 YMOIYAVQZHMYKO-UHFFFAOYSA-N 0.000 claims description 3
- NEBVWSHXGASCPA-UHFFFAOYSA-N n-[3-[(cyclopentylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CNC1CCCC1 NEBVWSHXGASCPA-UHFFFAOYSA-N 0.000 claims description 3
- HFJYWXYHBBNIPE-UHFFFAOYSA-N n-[3-[(cyclopropylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CNC1CC1 HFJYWXYHBBNIPE-UHFFFAOYSA-N 0.000 claims description 3
- PMYVIYLCXFHEFG-UHFFFAOYSA-N n-[3-[(dimethylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CN(C)C)=C1 PMYVIYLCXFHEFG-UHFFFAOYSA-N 0.000 claims description 3
- YSPRFZGDWDJEIV-UHFFFAOYSA-N n-[3-[2-(cyclopentylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCNC1CCCC1 YSPRFZGDWDJEIV-UHFFFAOYSA-N 0.000 claims description 3
- VLFPMHOMHHVGFL-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethoxy]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(OCCN(C)C)=C1 VLFPMHOMHHVGFL-UHFFFAOYSA-N 0.000 claims description 3
- XLMZJSDZMREDIT-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CCN(C)C)=C1 XLMZJSDZMREDIT-UHFFFAOYSA-N 0.000 claims description 3
- ARKUPPIJRKHOQJ-UHFFFAOYSA-N n-[4-(2-aminoethyl)phenyl]-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CCN)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 ARKUPPIJRKHOQJ-UHFFFAOYSA-N 0.000 claims description 3
- UBKCUPRGGJDJDT-UHFFFAOYSA-N n-[4-(2-aminoethyl)phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCN)C=C1 UBKCUPRGGJDJDT-UHFFFAOYSA-N 0.000 claims description 3
- VCVCXSPOZXMIFE-UHFFFAOYSA-N n-[4-(2-aminoethyl)phenyl]-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCN)C=C1 VCVCXSPOZXMIFE-UHFFFAOYSA-N 0.000 claims description 3
- BNBWRDTUJSXOCU-UHFFFAOYSA-N n-[4-(2-methoxyethoxy)phenyl]-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(OCCOC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 BNBWRDTUJSXOCU-UHFFFAOYSA-N 0.000 claims description 3
- ZJRUCIFBIBWCBX-UHFFFAOYSA-N n-[4-(aminomethyl)phenyl]-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CN)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 ZJRUCIFBIBWCBX-UHFFFAOYSA-N 0.000 claims description 3
- RYWLVHKOIQOBEP-UHFFFAOYSA-N n-[4-(aminomethyl)phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CN)C=C1 RYWLVHKOIQOBEP-UHFFFAOYSA-N 0.000 claims description 3
- SBGYWALMFBDTLU-UHFFFAOYSA-N n-[4-(aminomethyl)phenyl]-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CN)C=C1 SBGYWALMFBDTLU-UHFFFAOYSA-N 0.000 claims description 3
- MXTFGJHPLWKYSA-UHFFFAOYSA-N n-[4-[(cyclopentylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CNC1CCCC1 MXTFGJHPLWKYSA-UHFFFAOYSA-N 0.000 claims description 3
- HHNWSGKIGKJFDE-UHFFFAOYSA-N n-[4-[(cyclopropylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CNC1CC1 HHNWSGKIGKJFDE-UHFFFAOYSA-N 0.000 claims description 3
- ULGHTHURLGXNFB-UHFFFAOYSA-N n-[4-[(dimethylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CN(C)C)C=C1 ULGHTHURLGXNFB-UHFFFAOYSA-N 0.000 claims description 3
- JMUKEJDKNVEFCR-UHFFFAOYSA-N n-[4-[2-(cyclopentylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCNC1CCCC1 JMUKEJDKNVEFCR-UHFFFAOYSA-N 0.000 claims description 3
- WFRIHVMTHVXYFQ-UHFFFAOYSA-N n-[4-[2-(cyclopropylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCNC1CC1 WFRIHVMTHVXYFQ-UHFFFAOYSA-N 0.000 claims description 3
- QRDDBBUWGNAOTD-UHFFFAOYSA-N n-[4-[2-(dimethylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCN(C)C)C=C1 QRDDBBUWGNAOTD-UHFFFAOYSA-N 0.000 claims description 3
- COJTYKYQOPTTII-UHFFFAOYSA-N n-[[3-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 COJTYKYQOPTTII-UHFFFAOYSA-N 0.000 claims description 3
- CDZNBVIUVDVHNN-UHFFFAOYSA-N n-[[3-[(9-ethyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CNC(C)=O)=C1 CDZNBVIUVDVHNN-UHFFFAOYSA-N 0.000 claims description 3
- JJVBHRSWNYATBJ-UHFFFAOYSA-N n-[[3-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(NC=2N=C3N(C)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 JJVBHRSWNYATBJ-UHFFFAOYSA-N 0.000 claims description 3
- FOBBQUHCVZKXKB-UHFFFAOYSA-N n-[[4-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]-n-methylacetamide Chemical compound C1=CC(CN(C)C(C)=O)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 FOBBQUHCVZKXKB-UHFFFAOYSA-N 0.000 claims description 3
- WEWBMCRSGXJWDU-UHFFFAOYSA-N n-[[4-[(9-ethyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]-n-methylacetamide Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CN(C)C(C)=O)C=C1 WEWBMCRSGXJWDU-UHFFFAOYSA-N 0.000 claims description 3
- RIIQCCYYKOYGOR-UHFFFAOYSA-N n-[[4-[(9-ethyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CNC(C)=O)C=C1 RIIQCCYYKOYGOR-UHFFFAOYSA-N 0.000 claims description 3
- ZQXYZELNAKHPJZ-UHFFFAOYSA-N n-[[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound C1=CC(CNC(=O)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 ZQXYZELNAKHPJZ-UHFFFAOYSA-N 0.000 claims description 3
- SXVGDYQGWQGDIK-UHFFFAOYSA-N n-cyclopentyl-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1CC1N1C2=NC(NC3CCCC3)=NC=C2N=C1C1=CC=NC=C1 SXVGDYQGWQGDIK-UHFFFAOYSA-N 0.000 claims description 3
- KTNMDJYVQXCDKZ-UHFFFAOYSA-N n-methyl-n-[2-[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]acetamide Chemical compound C1=CC(CCN(C)C(C)=O)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 KTNMDJYVQXCDKZ-UHFFFAOYSA-N 0.000 claims description 3
- VAWSNENNHSSRON-UHFFFAOYSA-N n-methyl-n-[[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound C1=CC(CN(C)C(C)=O)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 VAWSNENNHSSRON-UHFFFAOYSA-N 0.000 claims description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims description 2
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims description 2
- OJAYHSXTIMOYHA-UHFFFAOYSA-N 3-ethyl-n-[4-(methylaminomethyl)phenyl]-2-pyridin-4-ylimidazo[4,5-b]pyridin-5-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CC=C1NC1=CC=C(CNC)C=C1 OJAYHSXTIMOYHA-UHFFFAOYSA-N 0.000 claims description 2
- PXRXHMJQHZQLIM-UHFFFAOYSA-N 4-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]-1-N,1-N-dimethylcyclohexa-1,5-diene-1,4-diamine Chemical compound NC1=NC=CC(=N1)C=1N(C2=NC(=NC=C2N1)C1(CC=C(C=C1)N(C)C)N)C1CC1 PXRXHMJQHZQLIM-UHFFFAOYSA-N 0.000 claims description 2
- NHBSGCNHKNJDPS-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-cyclopropyl-n-(3-methoxyphenyl)purin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=C(N)N=CC=4)=NC3=CN=2)=C1 NHBSGCNHKNJDPS-UHFFFAOYSA-N 0.000 claims description 2
- LKOGQCVPWVTMRE-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-cyclopropyl-n-phenylpurin-2-amine Chemical compound C1=NC(N)=CC(C=2N(C3=NC(NC=4C=CC=CC=4)=NC=C3N=2)C2CC2)=C1 LKOGQCVPWVTMRE-UHFFFAOYSA-N 0.000 claims description 2
- QUMUQLOQNDKVFM-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-ethyl-n-(4-fluoro-3-methoxyphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3C=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(OC)=C1 QUMUQLOQNDKVFM-UHFFFAOYSA-N 0.000 claims description 2
- LSNIYGFKFNDXFJ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NCCC=4SC=CC=4)=NC=C3N=2)C2CC2)=N1 LSNIYGFKFNDXFJ-UHFFFAOYSA-N 0.000 claims description 2
- MAIRAYHHNMOQSU-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(3-methoxyphenyl)purin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 MAIRAYHHNMOQSU-UHFFFAOYSA-N 0.000 claims description 2
- OYRYADSSHGWCAC-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(2-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC=C1NC1=NC=C(N=C(C=2N=C(N)N=CC=2)N2CC)C2=N1 OYRYADSSHGWCAC-UHFFFAOYSA-N 0.000 claims description 2
- GHWLXBMSIJWFNY-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(2-fluoro-4-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C=C1F GHWLXBMSIJWFNY-UHFFFAOYSA-N 0.000 claims description 2
- KQPCWOZUTPDLAJ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 KQPCWOZUTPDLAJ-UHFFFAOYSA-N 0.000 claims description 2
- ACQIYHOCKIGJAV-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-fluoro-2-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(F)=C1C ACQIYHOCKIGJAV-UHFFFAOYSA-N 0.000 claims description 2
- GPLOINKNIDSWSL-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(C)=C1 GPLOINKNIDSWSL-UHFFFAOYSA-N 0.000 claims description 2
- PIZQISPKSKBVSA-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-fluoro-3-methoxyphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(OC)=C1 PIZQISPKSKBVSA-UHFFFAOYSA-N 0.000 claims description 2
- WAVDPBGCYDVJMF-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2-chloro-4-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C(=CC(F)=CC=4)Cl)=NC=C3N=2)C2CC2)=N1 WAVDPBGCYDVJMF-UHFFFAOYSA-N 0.000 claims description 2
- MJSFVHQRTFALHV-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2-chloro-5-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C(=CC=C(F)C=4)Cl)=NC=C3N=2)C2CC2)=N1 MJSFVHQRTFALHV-UHFFFAOYSA-N 0.000 claims description 2
- CDWLGPFXJKITOC-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-9-cyclopropyl-n-(3-methoxyphenyl)purin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=C(Cl)N=CC=4)=NC3=CN=2)=C1 CDWLGPFXJKITOC-UHFFFAOYSA-N 0.000 claims description 2
- NRJVUCQSLBLQCU-UHFFFAOYSA-N 9-cyclopropyl-8-(1,3-thiazol-2-yl)-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3SC=CN=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 NRJVUCQSLBLQCU-UHFFFAOYSA-N 0.000 claims description 2
- APENBSBUJLGQKP-UHFFFAOYSA-N 9-cyclopropyl-8-(1-methylpyrrol-2-yl)-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound CN1C=CC=C1C(N(C1=N2)C3CC3)=NC1=CN=C2NCCC1=CC=CS1 APENBSBUJLGQKP-UHFFFAOYSA-N 0.000 claims description 2
- NDMUMHCYGMAQRN-UHFFFAOYSA-N 9-cyclopropyl-8-(1H-pyrrol-2-yl)-N-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3NC=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 NDMUMHCYGMAQRN-UHFFFAOYSA-N 0.000 claims description 2
- DWLPOLXCWATSCO-UHFFFAOYSA-N 9-cyclopropyl-8-pyridin-3-yl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3C=NC=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 DWLPOLXCWATSCO-UHFFFAOYSA-N 0.000 claims description 2
- CKNKWCNHIYCTIG-UHFFFAOYSA-N 9-cyclopropyl-8-pyridin-4-yl-n-(3,4,5-trimethoxyphenyl)purin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 CKNKWCNHIYCTIG-UHFFFAOYSA-N 0.000 claims description 2
- XVNMGGMAZPTHIV-UHFFFAOYSA-N 9-cyclopropyl-8-pyridin-4-yl-n-[3-(trifluoromethoxy)phenyl]purin-2-amine Chemical compound FC(F)(F)OC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 XVNMGGMAZPTHIV-UHFFFAOYSA-N 0.000 claims description 2
- NPAPKEPLPPFZHX-UHFFFAOYSA-N 9-cyclopropyl-n-(2,4-dimethoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC(OC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 NPAPKEPLPPFZHX-UHFFFAOYSA-N 0.000 claims description 2
- PHTKYENBCMCMIK-UHFFFAOYSA-N 9-cyclopropyl-n-(2-methoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 PHTKYENBCMCMIK-UHFFFAOYSA-N 0.000 claims description 2
- DSVLPARUQPEPGL-UHFFFAOYSA-N 9-cyclopropyl-n-(2-methylpropyl)-8-pyridin-4-ylpurin-2-amine Chemical compound C1CC1N1C2=NC(NCC(C)C)=NC=C2N=C1C1=CC=NC=C1 DSVLPARUQPEPGL-UHFFFAOYSA-N 0.000 claims description 2
- MKOLXIBPEPDIJM-UHFFFAOYSA-N 9-cyclopropyl-n-(2-phenylethyl)-8-pyridin-4-ylpurin-2-amine Chemical compound N=1C=C2N=C(C=3C=CN=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CC=C1 MKOLXIBPEPDIJM-UHFFFAOYSA-N 0.000 claims description 2
- NRUCIRIHQFSKIM-UHFFFAOYSA-N 9-cyclopropyl-n-(3,4-dimethoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 NRUCIRIHQFSKIM-UHFFFAOYSA-N 0.000 claims description 2
- WSQNCRJKXUFRCP-UHFFFAOYSA-N 9-cyclopropyl-n-(3-methoxyphenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(OC)C=CC=4)=NC=C3N=2)C2CC2)=N1 WSQNCRJKXUFRCP-UHFFFAOYSA-N 0.000 claims description 2
- UDPLWYLPGZGTPB-UHFFFAOYSA-N 9-cyclopropyl-n-(4-fluorophenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(F)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 UDPLWYLPGZGTPB-UHFFFAOYSA-N 0.000 claims description 2
- BVAAJTBOQVJYAL-UHFFFAOYSA-N 9-cyclopropyl-n-(4-methoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 BVAAJTBOQVJYAL-UHFFFAOYSA-N 0.000 claims description 2
- DPVCTRUNOHZWCK-UHFFFAOYSA-N 9-cyclopropyl-n-[(4-methylphenyl)methyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(C)=CC=C1CNC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 DPVCTRUNOHZWCK-UHFFFAOYSA-N 0.000 claims description 2
- NYAGIYGPFIPWSK-UHFFFAOYSA-N 9-cyclopropyl-n-[2-(2-fluorophenyl)ethyl]-8-pyridin-4-ylpurin-2-amine Chemical compound FC1=CC=CC=C1CCNC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 NYAGIYGPFIPWSK-UHFFFAOYSA-N 0.000 claims description 2
- FNAQKJULHGQKHE-UHFFFAOYSA-N 9-cyclopropyl-n-[2-(2-methoxyphenyl)ethyl]-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC=CC=C1CCNC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 FNAQKJULHGQKHE-UHFFFAOYSA-N 0.000 claims description 2
- SAUCCPWWVPCEBU-UHFFFAOYSA-N 9-ethyl-8-[2-(methylamino)pyrimidin-4-yl]-n-(3-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=CC(C)=C1 SAUCCPWWVPCEBU-UHFFFAOYSA-N 0.000 claims description 2
- GYFMZCFUFXNHJD-UHFFFAOYSA-N 9-ethyl-n-(3-ethylphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 GYFMZCFUFXNHJD-UHFFFAOYSA-N 0.000 claims description 2
- DOTMGRGARVEHMA-UHFFFAOYSA-N 9-ethyl-n-(3-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=CC(F)=C1 DOTMGRGARVEHMA-UHFFFAOYSA-N 0.000 claims description 2
- ZVGCPBYRIQCVMK-UHFFFAOYSA-N 9-ethyl-n-(4-fluoro-3-methoxyphenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(OC)=C1 ZVGCPBYRIQCVMK-UHFFFAOYSA-N 0.000 claims description 2
- HXIKLHCOHQNBDY-UHFFFAOYSA-N 9-ethyl-n-(4-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 HXIKLHCOHQNBDY-UHFFFAOYSA-N 0.000 claims description 2
- IEWVLVLAYSCVOY-UHFFFAOYSA-N 9-ethyl-n-(4-fluorophenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 IEWVLVLAYSCVOY-UHFFFAOYSA-N 0.000 claims description 2
- HATJPVJOVWDDHI-UHFFFAOYSA-N 9-methyl-8-pyridin-4-yl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NCCC1=CC=CS1 HATJPVJOVWDDHI-UHFFFAOYSA-N 0.000 claims description 2
- OMLDCPBOYYSBRO-UHFFFAOYSA-N 9-methyl-n-[4-(2-piperazin-1-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCN1CCNCC1 OMLDCPBOYYSBRO-UHFFFAOYSA-N 0.000 claims description 2
- VAJUBTFJMHCGTA-UHFFFAOYSA-N FC1=CC=C(C=C1)C1=NC2=NC(=NC=C2N1)N Chemical compound FC1=CC=C(C=C1)C1=NC2=NC(=NC=C2N1)N VAJUBTFJMHCGTA-UHFFFAOYSA-N 0.000 claims description 2
- UJQUJFKXQNLARQ-UHFFFAOYSA-N [4-[2-(4-fluoroanilino)-9-methylpurin-8-yl]pyridin-2-yl]methanol Chemical compound N1=C2N(C)C(C=3C=C(CO)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 UJQUJFKXQNLARQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- ZNMNMHHOKYRNQM-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1CC1N1C2=NC(NC=3C=C4OCOC4=CC=3)=NC=C2N=C1C1=CC=NC=C1 ZNMNMHHOKYRNQM-UHFFFAOYSA-N 0.000 claims description 2
- SVOLIXKSJUYSNV-UHFFFAOYSA-N n-(2,2-dimethyl-1,3-benzodioxol-5-yl)-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N=1C2=CN=C(NC=3C=C4OC(C)(C)OC4=CC=3)N=C2N(CC)C=1C1=CC=NC=C1 SVOLIXKSJUYSNV-UHFFFAOYSA-N 0.000 claims description 2
- FISCLDSEZJEGTR-UHFFFAOYSA-N n-(3,4-difluorophenyl)-9-ethyl-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(F)=C1 FISCLDSEZJEGTR-UHFFFAOYSA-N 0.000 claims description 2
- UJVDSFLOFDDOOH-UHFFFAOYSA-N n-(4-chlorophenyl)-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 UJVDSFLOFDDOOH-UHFFFAOYSA-N 0.000 claims description 2
- LQSQHRDYXHKTIV-UHFFFAOYSA-N n-(4-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]-9-(2,2,2-trifluoroethyl)purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)CC(F)(F)F)=N1 LQSQHRDYXHKTIV-UHFFFAOYSA-N 0.000 claims description 2
- AMHAUXXDQNPBJG-UHFFFAOYSA-N n-(4-fluorophenyl)-8-pyridin-4-yl-9-(2,2,2-trifluoroethyl)purin-2-amine Chemical compound C1=CC(F)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2CC(F)(F)F)C2=N1 AMHAUXXDQNPBJG-UHFFFAOYSA-N 0.000 claims description 2
- MJXUUHBPUUOUSI-UHFFFAOYSA-N n-(4-fluorophenyl)-9-methyl-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)C)=N1 MJXUUHBPUUOUSI-UHFFFAOYSA-N 0.000 claims description 2
- QMWWXCLWMSIYAD-UHFFFAOYSA-N n-[3-[2-(cyclopropylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCNC1CC1 QMWWXCLWMSIYAD-UHFFFAOYSA-N 0.000 claims description 2
- TZZAQIBVLVSJRQ-UHFFFAOYSA-N n-[4-[2-(dimethylamino)ethoxy]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(OCCN(C)C)C=C1 TZZAQIBVLVSJRQ-UHFFFAOYSA-N 0.000 claims description 2
- GTPLPLLKOJTSKV-UHFFFAOYSA-N n-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]quinolin-5-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C5=CC=CN=C5C=CC=4)=NC=C3N=2)C2CC2)=N1 GTPLPLLKOJTSKV-UHFFFAOYSA-N 0.000 claims description 2
- VILJIWHJLPKUBD-UHFFFAOYSA-N n-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]quinolin-6-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=C5C=CC=NC5=CC=4)=NC=C3N=2)C2CC2)=N1 VILJIWHJLPKUBD-UHFFFAOYSA-N 0.000 claims description 2
- OSJAUFLIZDQGAT-UHFFFAOYSA-N n-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]quinolin-8-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C5=NC=CC=C5C=CC=4)=NC=C3N=2)C2CC2)=N1 OSJAUFLIZDQGAT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical compound N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 claims 1
- WXPIEKTXAWQUCR-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3-chloro-4-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=C(Cl)C(F)=CC=4)=NC=C3N=2)C2CC2)=N1 WXPIEKTXAWQUCR-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- IGDUDDXLDGRHTG-UHFFFAOYSA-N N1=CC=C(C=C1)N1C2=NC(=NC=C2N=C1)N Chemical compound N1=CC=C(C=C1)N1C2=NC(=NC=C2N=C1)N IGDUDDXLDGRHTG-UHFFFAOYSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- 230000008569 process Effects 0.000 description 44
- 239000000203 mixture Substances 0.000 description 39
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 34
- 239000002904 solvent Substances 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 22
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 19
- 229940125396 insulin Drugs 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- NNWSQRLDWYRIRV-UHFFFAOYSA-N 2-chloro-n-cyclopropyl-5-nitropyrimidin-4-amine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1NC1CC1 NNWSQRLDWYRIRV-UHFFFAOYSA-N 0.000 description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 9
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 9
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 9
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 8
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 8
- 108091054455 MAP kinase family Proteins 0.000 description 8
- 102000043136 MAP kinase family Human genes 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000013067 intermediate product Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000004190 glucose uptake Effects 0.000 description 6
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical class [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 239000007868 Raney catalyst Substances 0.000 description 5
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 5
- 229910000564 Raney nickel Inorganic materials 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000011698 potassium fluoride Substances 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 4
- 108091008606 PDGF receptors Proteins 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 108010004469 allophycocyanin Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 235000003270 potassium fluoride Nutrition 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- GVTZVNRRGNBOJF-UHFFFAOYSA-N 4-(dimethoxymethyl)-n-methylpyrimidin-2-amine Chemical compound CNC1=NC=CC(C(OC)OC)=N1 GVTZVNRRGNBOJF-UHFFFAOYSA-N 0.000 description 3
- LKZISXNNURITGC-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-n-(4-fluorophenyl)-9-methylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=C(Cl)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 LKZISXNNURITGC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 description 3
- 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 150000001448 anilines Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000009229 glucose formation Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000011894 semi-preparative HPLC Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- UDAWCYHLAQVQQB-UHFFFAOYSA-N tert-butyl n-ethyl-n-[(4-nitrophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)N(CC)CC1=CC=C([N+]([O-])=O)C=C1 UDAWCYHLAQVQQB-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- PAMJENUKCYUKLC-UHFFFAOYSA-N 1-(4-nitrobenzyl)piperidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1CCCCC1 PAMJENUKCYUKLC-UHFFFAOYSA-N 0.000 description 2
- ZRDFCBNSANRTSD-UHFFFAOYSA-N 1-[2-(3-nitrophenyl)ethyl]piperidine Chemical compound [O-][N+](=O)C1=CC=CC(CCN2CCCCC2)=C1 ZRDFCBNSANRTSD-UHFFFAOYSA-N 0.000 description 2
- XVUGJKOKDLWVJJ-UHFFFAOYSA-N 2-(3-nitrophenyl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1=CC=CC([N+]([O-])=O)=C1 XVUGJKOKDLWVJJ-UHFFFAOYSA-N 0.000 description 2
- HGTHYMOKILRDHL-UHFFFAOYSA-N 2-(methylamino)pyrimidine-4-carbaldehyde Chemical compound CNC1=NC=CC(C=O)=N1 HGTHYMOKILRDHL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
- JFGUYYUCZSRMCF-UHFFFAOYSA-N 2-aminopyrimidine-4-carbaldehyde Chemical compound NC1=NC=CC(C=O)=N1 JFGUYYUCZSRMCF-UHFFFAOYSA-N 0.000 description 2
- OQGFAPKRSPWPHR-UHFFFAOYSA-N 2-chloro-4-n-ethylpyrimidine-4,5-diamine Chemical compound CCNC1=NC(Cl)=NC=C1N OQGFAPKRSPWPHR-UHFFFAOYSA-N 0.000 description 2
- JBMBVWROWJGFMG-UHFFFAOYSA-N 2-chloro-7h-purine Chemical compound ClC1=NC=C2NC=NC2=N1 JBMBVWROWJGFMG-UHFFFAOYSA-N 0.000 description 2
- YIXRYDFFJSCVSP-UHFFFAOYSA-N 2-chloro-9-ethyl-8-pyridin-4-ylpurine Chemical compound N=1C2=CN=C(Cl)N=C2N(CC)C=1C1=CC=NC=C1 YIXRYDFFJSCVSP-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 2
- RYMQBWJQKNOBFR-UHFFFAOYSA-N 4-n-cyclopropyl-2-n-(2-thiophen-2-ylethyl)pyrimidine-2,4,5-triamine Chemical compound N1=C(NC2CC2)C(N)=CN=C1NCCC1=CC=CS1 RYMQBWJQKNOBFR-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- RTJAUHQFEDUFFL-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(2-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC=C1C RTJAUHQFEDUFFL-UHFFFAOYSA-N 0.000 description 2
- ZSCUKTFACZMWCO-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,5-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(F)=CC=C1F ZSCUKTFACZMWCO-UHFFFAOYSA-N 0.000 description 2
- NUTDEBPDDVELNJ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3,5-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(C)=CC(C)=C1 NUTDEBPDDVELNJ-UHFFFAOYSA-N 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000017013 Heterogeneous Nuclear Ribonucleoprotein A1 Human genes 0.000 description 2
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000573522 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 238000006254 arylation reaction Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 239000000460 chlorine Chemical group 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000003271 compound fluorescence assay Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000005147 halomethylbenzenes Chemical class 0.000 description 2
- 102000057747 human MKNK1 Human genes 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000004155 insulin signaling pathway Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- ZMQPYUAJBGXGCB-UHFFFAOYSA-N n-[(4-nitrophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=C([N+]([O-])=O)C=C1 ZMQPYUAJBGXGCB-UHFFFAOYSA-N 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 2
- CCOXWRVWKFVFDG-UHFFFAOYSA-N pyrimidine-2-carbaldehyde Chemical compound O=CC1=NC=CC=N1 CCOXWRVWKFVFDG-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SMIXZZMSWYOQPW-UHFFFAOYSA-N (4-nitrophenyl)methylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=C([N+]([O-])=O)C=C1 SMIXZZMSWYOQPW-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- VJQCNCOGZPSOQZ-UHFFFAOYSA-N 1-Methylguanidine hydrochloride Chemical compound [Cl-].C[NH2+]C(N)=N VJQCNCOGZPSOQZ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- DWJDEJZHYRTMRR-UHFFFAOYSA-N 2,2-dimethoxypropanal Chemical compound COC(C)(OC)C=O DWJDEJZHYRTMRR-UHFFFAOYSA-N 0.000 description 1
- MHYPLWZTFXKBEA-UHFFFAOYSA-N 2-chloro-n-ethyl-5-nitropyrimidin-4-amine Chemical compound CCNC1=NC(Cl)=NC=C1[N+]([O-])=O MHYPLWZTFXKBEA-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- HVLUYXIJZLDNIS-UHFFFAOYSA-N 2-thiophen-2-ylethanamine Chemical compound NCCC1=CC=CS1 HVLUYXIJZLDNIS-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- AEFCUBQBTTVKDN-UHFFFAOYSA-N 3-(2-piperidin-1-ylethyl)aniline Chemical compound NC1=CC=CC(CCN2CCCCC2)=C1 AEFCUBQBTTVKDN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- ZHFFNLQQANCJEQ-UHFFFAOYSA-N 4-(2-morpholin-4-ylethoxy)aniline Chemical compound C1=CC(N)=CC=C1OCCN1CCOCC1 ZHFFNLQQANCJEQ-UHFFFAOYSA-N 0.000 description 1
- OQINWXZQCAIVNK-UHFFFAOYSA-N 4-(dimethoxymethyl)pyrimidin-2-amine Chemical compound COC(OC)C1=CC=NC(N)=N1 OQINWXZQCAIVNK-UHFFFAOYSA-N 0.000 description 1
- DRYFDUUAYSVNSN-UHFFFAOYSA-N 4-(piperidin-1-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCCCC1 DRYFDUUAYSVNSN-UHFFFAOYSA-N 0.000 description 1
- ANYJDIFHIHUTPB-UHFFFAOYSA-N 4-[9-ethyl-2-(4-fluorophenoxy)purin-8-yl]pyrimidin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1OC1=CC=C(F)C=C1 ANYJDIFHIHUTPB-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- LVILGAOSPDLNRM-UHFFFAOYSA-N 4-methylpyrimidine Chemical compound CC1=CC=NC=N1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- KNDQGRSIMXKUSP-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(4-fluorophenyl)-9-methylpurin-2-amine Chemical compound N1=C2N(C)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 KNDQGRSIMXKUSP-UHFFFAOYSA-N 0.000 description 1
- ZYSXILVXKJTJKB-UHFFFAOYSA-N 9-[(2,4-dimethoxyphenyl)methyl]-n-(4-fluorophenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC(OC)=CC=C1CN1C2=NC(NC=3C=CC(F)=CC=3)=NC=C2N=C1C1=CC=NC=C1 ZYSXILVXKJTJKB-UHFFFAOYSA-N 0.000 description 1
- LDDNXGPEDPDBKZ-UHFFFAOYSA-N 9-cyclopropyl-n-(3,5-dimethoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC(OC)=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 LDDNXGPEDPDBKZ-UHFFFAOYSA-N 0.000 description 1
- SYXKZMPXYKAWIZ-UHFFFAOYSA-N 9-cyclopropyl-n-(3-methoxyphenyl)-n-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC=CC(N(C)C=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 SYXKZMPXYKAWIZ-UHFFFAOYSA-N 0.000 description 1
- WTSPFSNVEDVUKQ-UHFFFAOYSA-N 9-ethyl-n-[4-[(propan-2-ylamino)methyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CNC(C)C)C=C1 WTSPFSNVEDVUKQ-UHFFFAOYSA-N 0.000 description 1
- UIVQKYBCYIRMFQ-UHFFFAOYSA-N 9-methyl-n-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1CN(C)CCN1CC1=CC=CC(NC=2N=C3N(C)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 UIVQKYBCYIRMFQ-UHFFFAOYSA-N 0.000 description 1
- NTIPFZGDPFRSAA-UHFFFAOYSA-N 9-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1CN(C)CCN1CC(C=C1)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 NTIPFZGDPFRSAA-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 0 CN(c1ncc2nc(*)[n](*)c2n1)*#C Chemical compound CN(c1ncc2nc(*)[n](*)c2n1)*#C 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000002241 Eukaryotic Initiation Factors Human genes 0.000 description 1
- 108010014863 Eukaryotic Initiation Factors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- UQPMANVRZYYQMD-UHFFFAOYSA-N N3-(4-fluorophenyl)-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine Chemical compound C=12C(N)=NC=NC2=NNC=1NC1=CC=C(F)C=C1 UQPMANVRZYYQMD-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000005018 aminopurines Chemical class 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N deuterated methanol Substances [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011738 major mineral Substances 0.000 description 1
- 235000011963 major mineral Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- IRZYBDYWVGMCSY-UHFFFAOYSA-N n-(4-methoxyphenyl)-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 IRZYBDYWVGMCSY-UHFFFAOYSA-N 0.000 description 1
- QYQYMVAVTKTFEK-UHFFFAOYSA-N n-[(4-aminophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=C(N)C=C1 QYQYMVAVTKTFEK-UHFFFAOYSA-N 0.000 description 1
- CRBKFFVPLITHLR-UHFFFAOYSA-N n-[(4-nitrophenyl)methyl]ethanamine Chemical compound CCNCC1=CC=C([N+]([O-])=O)C=C1 CRBKFFVPLITHLR-UHFFFAOYSA-N 0.000 description 1
- DQZATBKGAJSHGC-UHFFFAOYSA-N n-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]isoquinolin-5-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C5=CC=NC=C5C=CC=4)=NC=C3N=2)C2CC2)=N1 DQZATBKGAJSHGC-UHFFFAOYSA-N 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- GNURASXBKKXAOM-JGWLITMVSA-N oxido-[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexylidene]oxidanium Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=[O+][O-] GNURASXBKKXAOM-JGWLITMVSA-N 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010006693 promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- OKULHRWWYCFJAB-UHFFFAOYSA-N pyrimidine-4-carbaldehyde Chemical compound O=CC1=CC=NC=N1 OKULHRWWYCFJAB-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YRQMBQUMJFVZLF-UHFFFAOYSA-N tert-butyl n-(4-hydroxyphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(O)C=C1 YRQMBQUMJFVZLF-UHFFFAOYSA-N 0.000 description 1
- NCHPEYULQVABAW-UHFFFAOYSA-N tert-butyl n-[4-(2-morpholin-4-ylethoxy)phenyl]carbamate Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1OCCN1CCOCC1 NCHPEYULQVABAW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78080006P | 2006-03-09 | 2006-03-09 | |
| US60/780,800 | 2006-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080107466A true KR20080107466A (ko) | 2008-12-10 |
Family
ID=38371082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087024592A Withdrawn KR20080107466A (ko) | 2006-03-09 | 2007-03-09 | 대사 장애 치료용 8-헤테로아릴퓨린 mnk2 억제제 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7951803B2 (enExample) |
| EP (1) | EP1991547A2 (enExample) |
| JP (1) | JP2009529541A (enExample) |
| KR (1) | KR20080107466A (enExample) |
| CN (1) | CN101454325A (enExample) |
| AU (1) | AU2007222982A1 (enExample) |
| BR (1) | BRPI0709007A2 (enExample) |
| CA (1) | CA2646429A1 (enExample) |
| EA (1) | EA014907B1 (enExample) |
| MX (1) | MX2008011525A (enExample) |
| WO (1) | WO2007104053A2 (enExample) |
| ZA (1) | ZA200807715B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070225304A1 (en) * | 2005-09-06 | 2007-09-27 | Pharmacopeia Drug Discovery, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| AU2007309167A1 (en) * | 2006-10-20 | 2008-05-02 | N.V. Organon | Purines as PKC-theta inhibitors |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| NZ591176A (en) | 2008-08-22 | 2012-11-30 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
| EP2536720A1 (en) * | 2010-02-18 | 2012-12-26 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Triazolo [4, 5 - b]pyridin derivatives |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| JP5575274B2 (ja) * | 2010-02-26 | 2014-08-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物のためのmnkl/mnk2阻害活性を有する4−[シクロアルキルオキシ(ヘテロ)アリールアミノ]チエノ「2,3−d]ピリミジン |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| WO2014072244A1 (en) | 2012-11-09 | 2014-05-15 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| US20150051208A1 (en) * | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| ES2693520T3 (es) | 2013-12-04 | 2018-12-12 | Evotec International Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
| WO2015091156A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
| EP3140300B1 (en) | 2014-05-07 | 2019-08-14 | Evotec International GmbH | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| CN105001096B (zh) * | 2015-07-21 | 2017-07-21 | 沈阳化工研究院有限公司 | 一种制备4‑氨基‑n‑烷基苄胺的方法 |
| CN106008506B (zh) * | 2016-06-27 | 2018-02-13 | 山东大学 | 取代嘌呤类衍生物及其制备方法与应用 |
| FI3984523T3 (fi) | 2018-12-07 | 2025-10-21 | Neurocrine Biosciences Inc | Crf1-reseptorin antagonisti, lääkeformulaatioita ja niiden kiinteitä muotoja synnynnäisen lisämunuaisten liikakasvun hoitoon |
| CA3152590A1 (en) | 2019-09-27 | 2021-04-01 | Evan Smith | Crf receptor antagonists and methods of use |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| NZ304859A (en) | 1995-04-03 | 2000-01-28 | Novartis Ag | 4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives, medicaments and processes for the preparation thereof |
| ZA9810490B (en) * | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| SE0102147D0 (sv) | 2001-06-18 | 2001-06-18 | Pharmacia Ab | New methods |
| WO2003006465A1 (en) * | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
| DE60238929D1 (de) | 2001-10-29 | 2011-02-24 | Boehringer Ingelheim Int | Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind |
| US7105526B2 (en) * | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US20090054358A1 (en) * | 2004-07-19 | 2009-02-26 | The John Hopkins University | Flt3 inhibitors for immune suppression |
| WO2006045828A1 (en) * | 2004-10-29 | 2006-05-04 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting bicyclic pyrimidine derivatives |
| US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| AU2006232105A1 (en) * | 2005-04-05 | 2006-10-12 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
| US20070225304A1 (en) * | 2005-09-06 | 2007-09-27 | Pharmacopeia Drug Discovery, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| US20090023723A1 (en) * | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| EP1951234A2 (en) * | 2005-10-18 | 2008-08-06 | Janssen Pharmaceutica N.V. | Method of inhibiting flt3 kinase |
| US7989459B2 (en) * | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| TW200831104A (en) * | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| AU2007309167A1 (en) * | 2006-10-20 | 2008-05-02 | N.V. Organon | Purines as PKC-theta inhibitors |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| US20080220256A1 (en) * | 2007-03-09 | 2008-09-11 | Ues, Inc. | Methods of coating carbon/carbon composite structures |
-
2007
- 2007-03-09 MX MX2008011525A patent/MX2008011525A/es unknown
- 2007-03-09 CA CA002646429A patent/CA2646429A1/en not_active Abandoned
- 2007-03-09 AU AU2007222982A patent/AU2007222982A1/en not_active Abandoned
- 2007-03-09 US US11/684,262 patent/US7951803B2/en not_active Expired - Fee Related
- 2007-03-09 KR KR1020087024592A patent/KR20080107466A/ko not_active Withdrawn
- 2007-03-09 JP JP2008558554A patent/JP2009529541A/ja active Pending
- 2007-03-09 CN CNA2007800157773A patent/CN101454325A/zh active Pending
- 2007-03-09 BR BRPI0709007-2A patent/BRPI0709007A2/pt not_active IP Right Cessation
- 2007-03-09 EA EA200801897A patent/EA014907B1/ru not_active IP Right Cessation
- 2007-03-09 ZA ZA200807715A patent/ZA200807715B/xx unknown
- 2007-03-09 EP EP07758270A patent/EP1991547A2/en not_active Withdrawn
- 2007-03-09 WO PCT/US2007/063699 patent/WO2007104053A2/en not_active Ceased
-
2011
- 2011-05-27 US US13/118,166 patent/US20110230480A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110230480A1 (en) | 2011-09-22 |
| AU2007222982A1 (en) | 2007-09-13 |
| BRPI0709007A2 (pt) | 2011-06-21 |
| EP1991547A2 (en) | 2008-11-19 |
| US7951803B2 (en) | 2011-05-31 |
| WO2007104053A2 (en) | 2007-09-13 |
| CN101454325A (zh) | 2009-06-10 |
| ZA200807715B (en) | 2009-11-25 |
| CA2646429A1 (en) | 2007-09-13 |
| EA014907B1 (ru) | 2011-02-28 |
| EA200801897A1 (ru) | 2009-02-27 |
| US20080032971A1 (en) | 2008-02-07 |
| WO2007104053A3 (en) | 2007-11-01 |
| MX2008011525A (es) | 2008-09-18 |
| JP2009529541A (ja) | 2009-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080107466A (ko) | 대사 장애 치료용 8-헤테로아릴퓨린 mnk2 억제제 | |
| JP6892444B2 (ja) | Mnk1およびmnk2のイソインドリン、アザイソインドリン、ジヒドロインデノンならびにジヒドロアザインデノン阻害薬 | |
| KR102400920B1 (ko) | 리신 특이적 데메틸라제-1의 억제제 | |
| AU2015225745B2 (en) | Heterocyclic compounds | |
| KR101828187B1 (ko) | 신규 축합 피리미딘 화합물 또는 그 염 | |
| JP6663866B2 (ja) | リジン特異的なデメチラーゼ−1の阻害剤 | |
| EP3080100A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| KR20170031241A (ko) | 시클린-의존성 키나제 (cdk) 억제제로서의 2-h-인다졸 유도체 및 그의 치료적 용도 | |
| AU2010267815B2 (en) | Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | |
| WO2021011796A1 (en) | Inhibitors of cyclin-dependent kinases | |
| CN111683662B (zh) | 取代嘧啶类化合物及其药物组合物和治疗方法 | |
| JP2022523477A (ja) | ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物 | |
| EP4161657A1 (en) | Inhibitors of fibroblast growth factor receptor kinases | |
| US20250145599A1 (en) | Certain chemical entities, compositions, and methods | |
| SK142099A3 (en) | 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds | |
| CZ360199A3 (cs) | Sloučeniny 6,7-disubstituovaného-4- aminopyrido [2,3-dJ pyrimidinu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20081008 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |